A number of firms have modified their ratings and price targets on shares of AngioDynamics (NASDAQ: ANGO) recently:

  • 2/5/2018 – AngioDynamics was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 1/26/2018 – AngioDynamics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Despite trading below the broader industry in the last year, market’s solid response to Solero platform, especially within the Microwave Ablation space, is likely to boost AngioDynamics. The company has been offering a broad spectrum of products which has helped widen its commercial opportunities. AngioDynamics is also a leading player in the thrombolytic catheters space. The company boasts highly unique catheters like Uni-Fuse, SpeedLyser and Pulse Spray under the thrombus portfolio. On the flipside, the company’s Peripheral Vascular business segment witnessed a downside scenario. The company also had a high outstanding debt level at the end of the last quarter. AngioDynamics’ higher debts impose certain operating and financial restrictions which limit the company’s execution of the company’s core business strategies. The company also recalled the Acculis Microwave Tissue Ablation System recently.”
  • 1/22/2018 – AngioDynamics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $19.00 price target on the stock. According to Zacks, “Despite trading below the broader industry in the last year, market’s solid response to Solero platform, especially within the Microwave Ablation space, is likely to boost AngioDynamics. The company has been offering a broad spectrum of products which has helped widen its commercial opportunities. AngioDynamics is also a leading player in the thrombolytic catheters space. The company boasts highly unique catheters like Uni-Fuse, SpeedLyser and Pulse Spray under the thrombus portfolio. On the flipside, the company’s Peripheral Vascular business segment witnessed a downside scenario. The company also had a high outstanding debt level at the end of the second quarter. AngioDynamics’ higher debts impose certain operating and financial restrictions which limit the company’s execution of the company’s core business strategies. The company also recalled the Acculis Microwave Tissue Ablation System recently.”
  • 1/19/2018 – AngioDynamics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Despite trading below the broader industry in the last year, market’s solid response to Solero platform, especially within the Microwave Ablation space, is likely to boost AngioDynamics. The company has been offering a broad spectrum of products which has helped widen its commercial opportunities. AngioDynamics is also a leading player in the thrombolytic catheters space. The company boasts highly unique catheters like Uni-Fuse, SpeedLyser and Pulse Spray under the thrombus portfolio. On the flipside, the company’s Peripheral Vascular business segment witnessed a downside scenario. The company also had a high outstanding debt level at the end of the second quarter. AngioDynamics’ higher debts impose certain operating and financial restrictions which limit the company’s execution of the company’s core business strategies. The company also recalled the Acculis Microwave Tissue Ablation System recently.”
  • 1/8/2018 – AngioDynamics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $18.00 price target on the stock. According to Zacks, “AngioDynamics ended the second quarter of fiscal 2018 on a dismal note, missing the Zacks Consensus Estimates on both the counts. However, the company rides on the market’s positive response to Solero platform, especially within the Microwave Ablation space. AngioDynamics has been offering a broad spectrum of products which has helped widen its commercial opportunities. The company is also a leading player in the thrombolytic catheters space. The company boasts highly unique catheters like Uni-Fuse, SpeedLyser and Pulse Spray under the thrombus portfolio. On the flipside, the company’s Peripheral Vascular business segment witnessed a downside scenario. The company also had a high outstanding debt level at the end of the second quarter. AngioDynamics recalled the Acculis Microwave Tissue Ablation System under the Oncology and Surgery segment recently. Furthermore, AngioDynamics traded below the broader industry in the past year.”
  • 1/6/2018 – AngioDynamics was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 1/5/2018 – AngioDynamics was downgraded by analysts at Craig Hallum from a “buy” rating to a “hold” rating.
  • 1/2/2018 – AngioDynamics was downgraded by analysts at TheStreet from a “b-” rating to a “c” rating.

Shares of AngioDynamics, Inc. (NASDAQ:ANGO) traded down $0.25 during trading on Thursday, reaching $16.40. The company had a trading volume of 193,998 shares, compared to its average volume of 309,678. AngioDynamics, Inc. has a 52-week low of $14.80 and a 52-week high of $18.85. The firm has a market capitalization of $609.97, a PE ratio of -78.09, a P/E/G ratio of 1.54 and a beta of 0.98. The company has a quick ratio of 1.65, a current ratio of 2.56 and a debt-to-equity ratio of 0.17.

AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Thursday, January 4th. The medical instruments supplier reported $0.16 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.16. AngioDynamics had a positive return on equity of 4.63% and a negative net margin of 2.27%. The firm had revenue of $86.70 million for the quarter, compared to analysts’ expectations of $88.15 million. During the same quarter last year, the firm earned $0.19 earnings per share. The firm’s revenue for the quarter was down 2.6% compared to the same quarter last year. analysts predict that AngioDynamics, Inc. will post 0.72 EPS for the current fiscal year.

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

Receive News & Ratings for AngioDynamics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc and related companies with MarketBeat.com's FREE daily email newsletter.